INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (301, 'Zidovudine', 'Trastuzumab deruxtecan', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/301/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (302, 'Fenofibrate', 'Zidovudine', 'Moderate', 'Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if the risk of myopathy is increased during concurrent administration of other agents associated with myopathy, including corticosteroids, fibric acid derivatives, HMG-CoA reductase inhibitors, chloroquine, hydroxychloroquine, penicillamine, and lipid-lowering doses of niacin.', 'DDInter', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.', 'Synergism', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/302/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Indapamide, Bempedoic acid, Perindopril, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Colestipol, Bempedoic acid, Colesevelam, Alirocumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (303, 'Fenofibric acid', 'Zidovudine', 'Moderate', 'Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if the risk of myopathy is increased during concurrent administration of other agents associated with myopathy, including corticosteroids, fibric acid derivatives, HMG-CoA reductase inhibitors, chloroquine, hydroxychloroquine, penicillamine, and lipid-lowering doses of niacin.', 'DDInter', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.', 'Synergism', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/303/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Colestipol, Bempedoic acid, Colesevelam, Alirocumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (304, 'Fenoprofen', 'Zidovudine', 'Moderate', 'Limited clinical data suggest that the concomitant use of zidovudine with nonsteroidal anti-inflammatory agents may increase the risk of hematological toxicity and/or bleeding in HIV-positive patients with hemophilia.', 'DDInter', 'It is recommended to monitor patients for side effects and bleeding during concomitant use.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/304/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Misoprostol, Glucosamine, Oxaprozin, Chondroitin sulfate, Rofecoxib, Esomeprazole, Tolmetin, Meclofenamic acid, Valdecoxib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (305, 'Fingolimod', 'Zidovudine', 'Major', 'Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.', 'DDInter', 'The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.', 'Synergism', 'The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/305/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (306, 'Floxuridine', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/306/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (307, 'Fluconazole', 'Zidovudine', 'Moderate', 'Fluconazole may significantly reduce zidovudine clearance, and increase its elimination half-life and AUC. The mechanism is unknown but may be related to inhibition of its hepatic metabolism.', 'DDInter', 'Patients receiving concomitant fluconazole and zidovudine should be monitored for clinical and laboratory evidence of zidovudine toxicity such as anemia, neutropenia, abnormal liver function tests, myopathy, or lactic acidosis. Zidovudine dose reductions or discontinuation of fluconazole may be necessary.', 'Metabolism', 'Patients receiving concomitant fluconazole and zidovudine should be monitored for clinical and laboratory evidence of zidovudine toxicity such as anemia, neutropenia, abnormal liver function tests, myopathy, or lactic acidosis.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/307/', '', 'Tinidazole, Tetracycline, Cefepime, Norfloxacin, Cefuroxime, Secnidazole, Cefixime, Amikacin, Levofloxacin, Micafungin, Caspofungin, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Brincidofovir, Elbasvir, Darunavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (308, 'Flucytosine', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/308/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Micafungin, Caspofungin, Posaconazole, Oteseconazole, Anidulafungin, Voriconazole, Salicylic acid, Selenium Sulfide, Thiabendazole, Ciclopirox, Griseofulvin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (309, 'Fludarabine', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/309/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (310, 'Fludrocortisone', 'Zidovudine', 'Moderate', 'Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if the risk of myopathy is increased during concurrent administration of other agents associated with myopathy, including corticosteroids, fibric acid derivatives, HMG-CoA reductase inhibitors, chloroquine, hydroxychloroquine, penicillamine, and lipid-lowering doses of niacin.', 'DDInter', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.', 'Synergism', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/310/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 'Fluocinolone acetonide, Fluocinolone acetonide, Fluorometholone, Deflazacort', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (311, 'Fluorouracil', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/311/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (312, 'Flurazepam', 'Zidovudine', 'Minor', 'One study has suggested that patients receiving zidovudine and a benzodiazepine concomitantly may demonstrate increased plasma clearance of the benzodiazepine. That study also has suggested that patients on concomitant therapy may experience an increased number of headaches.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/312/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Telaprevir, Velpatasvir, More', 'Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (313, 'Flurbiprofen', 'Zidovudine', 'Moderate', 'Limited clinical data suggest that the concomitant use of zidovudine with nonsteroidal anti-inflammatory agents may increase the risk of hematological toxicity and/or bleeding in HIV-positive patients with hemophilia.', 'DDInter', 'It is recommended to monitor patients for side effects and bleeding during concomitant use.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/313/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Tolmetin, Tolazoline, Meclofenamic acid, Dimethyl sulfoxide, Misoprostol, Glucosamine, Oxaprozin, Chondroitin sulfate, Rofecoxib, Esomeprazole, Tolmetin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (314, 'Fluvastatin', 'Zidovudine', 'Moderate', 'Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if the risk of myopathy is increased during concurrent administration of other agents associated with myopathy, including corticosteroids, fibric acid derivatives, HMG-CoA reductase inhibitors, chloroquine, hydroxychloroquine, penicillamine, and lipid-lowering doses of niacin.', 'DDInter', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.', 'Synergism', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/314/', '', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Colestipol, Bempedoic acid, Colesevelam, Alirocumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (315, 'Foscarnet', 'Zidovudine', 'Moderate', 'The potential bone marrow toxicity of foscarnet and zidovudine may be additive. Concomitant therapy may therefore increase the risk of anemia and other forms of myelosuppression.', 'DDInter', 'Patients should be closely monitored for evidence of hematologic effects (e.g., granulocytopenia, anemia, leukopenia, thrombocytopenia).', 'Synergism', 'Patients should be closely monitored for evidence of hematologic effects (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/315/', '', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Etravirine, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (316, 'Fosphenytoin', 'Zidovudine', 'Minor', 'One study has suggested that zidovudine may have variable effects on plasma phenytoin levels. Increased levels, decreased levels, and no change have been reported. If zidovudine and phenytoin must be used together, close observation for altered clinical and laboratory effects is recommended.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/316/', '', 'Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (317, 'Ganciclovir', 'Zidovudine', 'Major', 'Limited data concerning the coadministration of ganciclovir and zidovudine do not suggest the potential for a clinically significant pharmacokinetic interaction. However, the possibility of increased risk and severity of hematologic toxicity, especially neutropenia and anemia, due to additive myelosuppressive effects should be considered during concomitant therapy. The majority of patients may be unable to tolerate full dosages of these drugs in combination.', 'DDInter', 'It is best to avoid the use of zidovudine with ganciclovir or its prodrug, valganciclovir, whenever possible. If simultaneous therapy is deemed necessary, reduced dosages of one (usually zidovudine) or both drugs may be required. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended. Alternatively, a less myelotoxic agent such as foscarnet may be considered in lieu of ganciclovir to treat cytomegalovirus infections in immunocompromised patients receiving zidovudine.', 'Synergism', 'It is best to avoid the use of zidovudine with ganciclovir or its prodrug, valganciclovir, whenever possible.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/317/', '', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (318, 'Gemcitabine', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/318/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (319, 'Gemfibrozil', 'Zidovudine', 'Moderate', 'Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if the risk of myopathy is increased during concurrent administration of other agents associated with myopathy, including corticosteroids, fibric acid derivatives, HMG-CoA reductase inhibitors, chloroquine, hydroxychloroquine, penicillamine, and lipid-lowering doses of niacin.', 'DDInter', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.', 'Synergism', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/319/', '', 'Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Colestipol, Bempedoic acid, Colesevelam, Alirocumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (320, 'Gemtuzumab ozogamicin', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/320/', '', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (321, 'Givosiran', 'Zidovudine', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.', 'DDInter', 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/321/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (322, 'Golimumab', 'Zidovudine', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).', 'DDInter', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/322/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (323, 'Halazepam', 'Zidovudine', 'Minor', 'One study has suggested that patients receiving zidovudine and a benzodiazepine concomitantly may demonstrate increased plasma clearance of the benzodiazepine. That study also has suggested that patients on concomitant therapy may experience an increased number of headaches.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/323/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', 'Meprobamate, Buspirone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (324, 'Hydrocortisone', 'Zidovudine', 'Moderate', 'Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if the risk of myopathy is increased during concurrent administration of other agents associated with myopathy, including corticosteroids, fibric acid derivatives, HMG-CoA reductase inhibitors, chloroquine, hydroxychloroquine, penicillamine, and lipid-lowering doses of niacin.', 'DDInter', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.', 'Synergism', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/324/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More', 'Fluocinolone acetonide, Fluorometholone, Tetracycline, Minocycline, Doxycycline, Clotrimazole, Epinephrine, Chlorhexidine, Neomycin, Fluocinolone acetonide, Salicylic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (325, 'Hydroxychloroquine', 'Zidovudine', 'Moderate', 'Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if the risk of myopathy is increased during concurrent administration of other agents associated with myopathy, including corticosteroids, fibric acid derivatives, HMG-CoA reductase inhibitors, chloroquine, hydroxychloroquine, penicillamine, and lipid-lowering doses of niacin.', 'DDInter', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.', 'Synergism', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/325/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Dolutegravir, More', 'Artesunate, Mefloquine, Lumefantrine, Artemether, Tafenoquine, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (326, 'Hydroxyurea', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/326/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (327, 'Ibritumomab tiuxetan', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/327/', '', 'Iodide I-131', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (328, 'Ibrutinib', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/328/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (329, 'Ibuprofen', 'Zidovudine', 'Moderate', 'Limited clinical data suggest that the concomitant use of zidovudine with nonsteroidal anti-inflammatory agents may increase the risk of hematological toxicity and/or bleeding in HIV-positive patients with hemophilia.', 'DDInter', 'It is recommended to monitor patients for side effects and bleeding during concomitant use.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/329/', '', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, Dolutegravir, More', 'Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Bromocriptine, Ranolazine, Ubidecarenone, Ivabradine, Adenosine, Regadenoson, Misoprostol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (330, 'Idarubicin', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/330/', '', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Etravirine, Dolutegravir, More', 'Valrubicin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (331, 'Idelalisib', 'Zidovudine', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', 'DDInter', 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/331/', '', 'Cabotegravir, Simeprevir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Famciclovir, Ribavirin, Tecovirimat, Maribavir, More', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (332, 'Ifosfamide', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/332/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (333, 'Indinavir', 'Zidovudine', 'Minor', 'Indinavir has been shown to increase the area under the plasma concentration-time curves of the reverse transcriptase inhibitors zidovudine and stavudine by up to 36% and 25%, respectively. Concomitant use has inconsistently affected indinavir plasma concentrations, which have increased by up to 13% or have shown no change. The mechanism of the interaction is not clearly understood, but it may be related to the effects of these drugs on hepatic enzymes. Dosage adjustments are unlikely to be necessary, although it may be appropriate to monitor the patient for zidovudine and/or stavudine toxicity.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/333/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Glecaprevir, Cabotegravir, Zanamivir, Lenacapavir, Valaciclovir, Telaprevir, Velpatasvir, Rilpivirine, Oseltamivir, Remdesivir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (334, 'Indomethacin', 'Zidovudine', 'Moderate', 'Limited clinical data suggest that the concomitant use of zidovudine with nonsteroidal anti-inflammatory agents may increase the risk of hematological toxicity and/or bleeding in HIV-positive patients with hemophilia.', 'DDInter', 'It is recommended to monitor patients for side effects and bleeding during concomitant use.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/334/', '', 'Fluocinolone acetonide, Fluorometholone, Misoprostol, Glucosamine, Oxaprozin, Chondroitin sulfate, Rofecoxib, Esomeprazole, Tolmetin, Meclofenamic acid, Valdecoxib, More', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (335, 'Infliximab', 'Zidovudine', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).', 'DDInter', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/335/', '', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (336, 'Inotuzumab ozogamicin', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/336/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (337, 'Interferon alfa-2a, Recombinant', 'Zidovudine', 'Major', 'The coadministration of interferons and zidovudine (AZT) may result in severe bone marrow toxicity, most often manifested as granulocytopenia and/or thrombocytopenia. The precise mechanism is unknown. These agents are individually myelotoxic, with potentially additive or synergistic effects; interferons may also decrease the metabolism of zidovudine.', 'DDInter', 'Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons. Complete blood counts, differential and platelet counts should be performed regularly and drug dosages adjusted accordingly. Patients should be advised to promptly report symptoms such as chills, fever, sore throat, pale skin, or unusual fatigue to their physician. Cessation of one or all drugs may be necessary if toxicity develops.', 'Synergism', 'Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/337/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (338, 'Interferon alfa-2b', 'Zidovudine', 'Major', 'The coadministration of interferons and zidovudine (AZT) may result in severe bone marrow toxicity, most often manifested as granulocytopenia and/or thrombocytopenia. The precise mechanism is unknown. These agents are individually myelotoxic, with potentially additive or synergistic effects; interferons may also decrease the metabolism of zidovudine.', 'DDInter', 'Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons. Complete blood counts, differential and platelet counts should be performed regularly and drug dosages adjusted accordingly. Patients should be advised to promptly report symptoms such as chills, fever, sore throat, pale skin, or unusual fatigue to their physician. Cessation of one or all drugs may be necessary if toxicity develops.', 'Synergism', 'Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/338/', '', 'Oprelvekin, Elapegademase, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (339, 'Interferon alfa-n1', 'Zidovudine', 'Major', 'The coadministration of interferons and zidovudine (AZT) may result in severe bone marrow toxicity, most often manifested as granulocytopenia and/or thrombocytopenia. The precise mechanism is unknown. These agents are individually myelotoxic, with potentially additive or synergistic effects; interferons may also decrease the metabolism of zidovudine.', 'DDInter', 'Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons. Complete blood counts, differential and platelet counts should be performed regularly and drug dosages adjusted accordingly. Patients should be advised to promptly report symptoms such as chills, fever, sore throat, pale skin, or unusual fatigue to their physician. Cessation of one or all drugs may be necessary if toxicity develops.', 'Synergism', 'Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/339/', '', 'Oprelvekin, Elapegademase, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (340, 'Interferon alfa-n3', 'Zidovudine', 'Major', 'The coadministration of interferons and zidovudine (AZT) may result in severe bone marrow toxicity, most often manifested as granulocytopenia and/or thrombocytopenia. The precise mechanism is unknown. These agents are individually myelotoxic, with potentially additive or synergistic effects; interferons may also decrease the metabolism of zidovudine.', 'DDInter', 'Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons. Complete blood counts, differential and platelet counts should be performed regularly and drug dosages adjusted accordingly. Patients should be advised to promptly report symptoms such as chills, fever, sore throat, pale skin, or unusual fatigue to their physician. Cessation of one or all drugs may be necessary if toxicity develops.', 'Synergism', 'Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/340/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (341, 'Interferon alfacon-1', 'Zidovudine', 'Major', 'The coadministration of interferons and zidovudine (AZT) may result in severe bone marrow toxicity, most often manifested as granulocytopenia and/or thrombocytopenia. The precise mechanism is unknown. These agents are individually myelotoxic, with potentially additive or synergistic effects; interferons may also decrease the metabolism of zidovudine.', 'DDInter', 'Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons. Complete blood counts, differential and platelet counts should be performed regularly and drug dosages adjusted accordingly. Patients should be advised to promptly report symptoms such as chills, fever, sore throat, pale skin, or unusual fatigue to their physician. Cessation of one or all drugs may be necessary if toxicity develops.', 'Synergism', 'Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/341/', '', 'Oprelvekin, Elapegademase, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (342, 'Interferon beta-1a', 'Zidovudine', 'Major', 'The coadministration of interferons and zidovudine (AZT) may result in severe bone marrow toxicity, most often manifested as granulocytopenia and/or thrombocytopenia. The precise mechanism is unknown. These agents are individually myelotoxic, with potentially additive or synergistic effects; interferons may also decrease the metabolism of zidovudine.', 'DDInter', 'Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons. Complete blood counts, differential and platelet counts should be performed regularly and drug dosages adjusted accordingly. Patients should be advised to promptly report symptoms such as chills, fever, sore throat, pale skin, or unusual fatigue to their physician. Cessation of one or all drugs may be necessary if toxicity develops.', 'Synergism', 'Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/342/', '', 'Oprelvekin, Elapegademase, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Etravirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (343, 'Interferon beta-1b', 'Zidovudine', 'Major', 'The coadministration of interferons and zidovudine (AZT) may result in severe bone marrow toxicity, most often manifested as granulocytopenia and/or thrombocytopenia. The precise mechanism is unknown. These agents are individually myelotoxic, with potentially additive or synergistic effects; interferons may also decrease the metabolism of zidovudine.', 'DDInter', 'Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons. Complete blood counts, differential and platelet counts should be performed regularly and drug dosages adjusted accordingly. Patients should be advised to promptly report symptoms such as chills, fever, sore throat, pale skin, or unusual fatigue to their physician. Cessation of one or all drugs may be necessary if toxicity develops.', 'Synergism', 'Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/343/', '', 'Oprelvekin, Elapegademase, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (344, 'Interferon gamma-1b', 'Zidovudine', 'Major', 'The coadministration of interferons and zidovudine (AZT) may result in severe bone marrow toxicity, most often manifested as granulocytopenia and/or thrombocytopenia. The precise mechanism is unknown. These agents are individually myelotoxic, with potentially additive or synergistic effects; interferons may also decrease the metabolism of zidovudine.', 'DDInter', 'Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons. Complete blood counts, differential and platelet counts should be performed regularly and drug dosages adjusted accordingly. Patients should be advised to promptly report symptoms such as chills, fever, sore throat, pale skin, or unusual fatigue to their physician. Cessation of one or all drugs may be necessary if toxicity develops.', 'Synergism', 'Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/344/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (345, 'Iobenguane (I-131)', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/345/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (346, 'Zidovudine', 'Tositumomab (I-131)', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/346/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (347, 'Irinotecan', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/347/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (348, 'Irinotecan (liposomal)', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/348/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (349, 'Isatuximab', 'Zidovudine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/349/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (350, 'Zidovudine', 'Ixabepilone', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/350/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 'Valrubicin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (351, 'Zidovudine', 'Ixazomib', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/351/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, More', 'Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (352, 'Zidovudine', 'Ketoprofen', 'Moderate', 'Limited clinical data suggest that the concomitant use of zidovudine with nonsteroidal anti-inflammatory agents may increase the risk of hematological toxicity and/or bleeding in HIV-positive patients with hemophilia.', 'DDInter', 'It is recommended to monitor patients for side effects and bleeding during concomitant use.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/352/', '', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Misoprostol, Glucosamine, Oxaprozin, Chondroitin sulfate, Rofecoxib, Esomeprazole, Tolmetin, Meclofenamic acid, Valdecoxib, Tolmetin, Tolazoline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (353, 'Zidovudine', 'Ketorolac', 'Moderate', 'Limited clinical data suggest that the concomitant use of zidovudine with nonsteroidal anti-inflammatory agents may increase the risk of hematological toxicity and/or bleeding in HIV-positive patients with hemophilia.', 'DDInter', 'It is recommended to monitor patients for side effects and bleeding during concomitant use.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/353/', '', 'Misoprostol, Glucosamine, Oxaprozin, Chondroitin sulfate, Rofecoxib, Esomeprazole, Tolmetin, Meclofenamic acid, Valdecoxib, Homatropine, Atropine, More', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (354, 'Zidovudine', 'Leflunomide', 'Major', 'The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.', 'DDInter', 'Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide''s active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.', 'Synergism', 'Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/354/', '', 'Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Dolutegravir, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (355, 'Zidovudine', 'Lenalidomide', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/355/', '', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (356, 'Zidovudine', 'Levamisole', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/356/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Thiabendazole, Pyrantel, Ivermectin, Piperazine, Mebendazole, Albendazole', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (357, 'Zidovudine', 'Linezolid', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/357/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Tinidazole, Oritavancin, Daptomycin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (358, 'Zidovudine', 'Lithium carbonate', 'Minor', 'According to one report, lithium carbonate may be useful in maintaining adequate neutrophil counts in AIDS patients taking zidovudine.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/358/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (359, 'Zidovudine', 'Lomustine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/359/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (360, 'Zidovudine', 'Lorazepam', 'Minor', 'One study has suggested that patients receiving zidovudine and a benzodiazepine concomitantly may demonstrate increased plasma clearance of the benzodiazepine. That study also has suggested that patients on concomitant therapy may experience an increased number of headaches.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/360/', '', 'Meprobamate, Buspirone', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (361, 'Zidovudine', 'Lorlatinib', 'Moderate', 'Coadministration with lorlatinib may decrease the plasma concentrations of drugs that are substrates of the uridine diphosphate glucuronosyl transferase (UGT) enzymes. The proposed mechanism involves decreased metabolic clearance due to induction of UGT by lorlatinib.', 'DDInter', 'Caution is advised when lorlatinib is used concurrently with drugs that are known UGT substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lorlatinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when lorlatinib is used concurrently with drugs that are known UGT substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/361/', '', 'Lamivudine, Cabotegravir, Simeprevir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, Elbasvir, More', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (362, 'Zidovudine', 'Lovastatin', 'Moderate', 'Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if the risk of myopathy is increased during concurrent administration of other agents associated with myopathy, including corticosteroids, fibric acid derivatives, HMG-CoA reductase inhibitors, chloroquine, hydroxychloroquine, penicillamine, and lipid-lowering doses of niacin.', 'DDInter', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.', 'Synergism', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/362/', '', 'Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Colestipol, Bempedoic acid, Colesevelam, Alirocumab, Indapamide, Bempedoic acid, Perindopril', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Rilpivirine, Dolutegravir, Brincidofovir, Elbasvir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (363, 'Zidovudine', 'Lurbinectedin', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/363/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More', 'Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (364, 'Zidovudine', 'Lutetium Lu 177 dotatate', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/364/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (365, 'Zidovudine', 'Mechlorethamine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/365/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (366, 'Zidovudine', 'Mefenamic acid', 'Moderate', 'Limited clinical data suggest that the concomitant use of zidovudine with nonsteroidal anti-inflammatory agents may increase the risk of hematological toxicity and/or bleeding in HIV-positive patients with hemophilia.', 'DDInter', 'It is recommended to monitor patients for side effects and bleeding during concomitant use.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/366/', '', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Misoprostol, Glucosamine, Oxaprozin, Chondroitin sulfate, Rofecoxib, Esomeprazole, Tolmetin, Meclofenamic acid, Valdecoxib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (367, 'Zidovudine', 'Meloxicam', 'Moderate', 'Limited clinical data suggest that the concomitant use of zidovudine with nonsteroidal anti-inflammatory agents may increase the risk of hematological toxicity and/or bleeding in HIV-positive patients with hemophilia.', 'DDInter', 'It is recommended to monitor patients for side effects and bleeding during concomitant use.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/367/', '', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Dolutegravir, More', 'Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (368, 'Zidovudine', 'Melphalan', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/368/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (369, 'Zidovudine', 'Mephenytoin', 'Minor', 'One study has suggested that zidovudine may have variable effects on plasma phenytoin levels. Increased levels, decreased levels, and no change have been reported. If zidovudine and phenytoin must be used together, close observation for altered clinical and laboratory effects is recommended.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/369/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (370, 'Zidovudine', 'Mercaptopurine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/370/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (371, 'Zidovudine', 'Methadone', 'Moderate', 'One study has suggested that combining methadone with zidovudine may increase blood levels of zidovudine and reduce effects of methadone. The mechanism is unknown but may be related to and inhibition of zidovudine metabolism by methadone and induction of methadone metabolism by zidovudine.', 'DDInter', 'If these drugs must be used together, close observation for clinical and laboratory evidence of zidovudine toxicity (anemia, granulocytopenia, myalgia, nausea, vomiting) and altered methadone efficacy is recommended.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/371/', '', 'Diamorphine, Acamprosate, Lofexidine, Varenicline, Disulfiram, Levacetylmethadol, Nalmefene, Nicotine, Codeine, Oliceridine, Oxymorphone, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (372, 'Zidovudine', 'Methotrexate', 'Moderate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.', 'DDInter', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/372/', '', 'Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Telaprevir, Velpatasvir, Etravirine, Dolutegravir, Cobicistat, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (373, 'Zidovudine', 'Methylprednisolone', 'Moderate', 'Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if the risk of myopathy is increased during concurrent administration of other agents associated with myopathy, including corticosteroids, fibric acid derivatives, HMG-CoA reductase inhibitors, chloroquine, hydroxychloroquine, penicillamine, and lipid-lowering doses of niacin.', 'DDInter', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.', 'Synergism', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/373/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Brincidofovir, More', 'Minocycline, Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Deflazacort, Fluocinolone acetonide, Fluocinonide, Fluorometholone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (374, 'Zidovudine', 'Midazolam', 'Minor', 'One study has suggested that patients receiving zidovudine and a benzodiazepine concomitantly may demonstrate increased plasma clearance of the benzodiazepine. That study also has suggested that patients on concomitant therapy may experience an increased number of headaches.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/374/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', 'Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (375, 'Zidovudine', 'Mipomersen', 'Major', 'Coadministration of mipomersen with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Mipomersen can cause elevations in serum transaminases and hepatic steatosis.', 'DDInter', 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, lomitapide, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Mipomersen has not been studied with other LDL-lowering agents that can also increase hepatic fat, thus concomitant use is not recommended. Patients treated with mipomersen should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/375/', '', 'Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Etravirine, More', 'Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Colestipol, Bempedoic acid, Colesevelam, Alirocumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (376, 'Zidovudine', 'Mitomycin', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/376/', '', 'Valrubicin', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (377, 'Zidovudine', 'Mitoxantrone', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/377/', '', 'Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Rilpivirine, Etravirine, Dolutegravir, Oseltamivir, More', 'Valrubicin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (378, 'Zidovudine', 'Mogamulizumab', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/378/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (379, 'Zidovudine', 'Monomethyl fumarate', 'Moderate', 'The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.', 'DDInter', 'The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.', 'Synergism', 'The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/379/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (380, 'Zidovudine', 'Nabumetone', 'Moderate', 'Limited clinical data suggest that the concomitant use of zidovudine with nonsteroidal anti-inflammatory agents may increase the risk of hematological toxicity and/or bleeding in HIV-positive patients with hemophilia.', 'DDInter', 'It is recommended to monitor patients for side effects and bleeding during concomitant use.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/380/', '', 'Misoprostol, Glucosamine, Oxaprozin, Chondroitin sulfate, Rofecoxib, Esomeprazole, Tolmetin, Meclofenamic acid, Valdecoxib', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (381, 'Zidovudine', 'Naltrexone', 'Moderate', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.', 'DDInter', 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.', 'Synergism', 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/381/', '', 'Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Etravirine, More', 'Codeine, Oliceridine, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Dezocine, Tramadol, Opium, Dextropropoxyphene, Pentazocine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (382, 'Zidovudine', 'Naproxen', 'Moderate', 'Limited clinical data suggest that the concomitant use of zidovudine with nonsteroidal anti-inflammatory agents may increase the risk of hematological toxicity and/or bleeding in HIV-positive patients with hemophilia.', 'DDInter', 'It is recommended to monitor patients for side effects and bleeding during concomitant use.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/382/', '', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Bromocriptine, Tolmetin, Tolazoline, Meclofenamic acid, Dimethyl sulfoxide, Misoprostol, Glucosamine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (383, 'Zidovudine', 'Natalizumab', 'Major', 'Concomitant or recent use of immunosuppressant, immunomodulating, or antineoplastic agents in patients treated with natalizumab may increase the risk of infections including progressive multifocal leukoencephalopathy (PML), a severely disabling, potentially fatal opportunistic viral infection of the brain.', 'DDInter', 'The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established. In general, patients receiving chronic therapy with such agents should not be treated with natalizumab due to potentially increased risk of PML and other serious infections. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Due to the long half-life of natalizumab, immune effects are possible for up to 2 to 3 months following its discontinuation.', 'Synergism', 'The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/383/', '', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (384, 'Zidovudine', 'Naxitamab', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/384/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (385, 'Zidovudine', 'Nelarabine', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/385/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (386, 'Zidovudine', 'Niacin', 'Moderate', 'Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if the risk of myopathy is increased during concurrent administration of other agents associated with myopathy, including corticosteroids, fibric acid derivatives, HMG-CoA reductase inhibitors, chloroquine, hydroxychloroquine, penicillamine, and lipid-lowering doses of niacin.', 'DDInter', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.', 'Synergism', 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/386/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Colestipol, Bempedoic acid, Colesevelam, Alirocumab, Indapamide, Bempedoic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (387, 'Zidovudine', 'Nilotinib', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/387/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (388, 'Zidovudine', 'Niraparib', 'Moderate', 'Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with niraparib.', 'DDInter', 'Caution is advised if niraparib is prescribed with other myelosuppressive agents.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/388/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (389, 'Zidovudine', 'Obinutuzumab', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/389/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (390, 'Zidovudine', 'Ocrelizumab', 'Moderate', 'The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.', 'DDInter', 'The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.', 'Synergism', 'The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/390/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (391, 'Zidovudine', 'Ofatumumab', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/391/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (392, 'Zidovudine', 'Olaparib', 'Moderate', 'Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with olaparib.', 'DDInter', 'Caution is advised if olaparib is prescribed with other myelosuppressive agents. Complete blood counts should be performed at baseline and monthly thereafter. Do not start olaparib until patients have recovered from hematologic toxicity caused by previous chemotherapy.', 'Synergism', 'Caution is advised if olaparib is prescribed with other myelosuppressive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/392/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Rilpivirine, Dolutegravir, More', 'Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (393, 'Zidovudine', 'Omacetaxine mepesuccinate', 'Moderate', 'The use of omacetaxine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Omacetaxine alone may cause severe myelosuppression, neutropenia, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other hematotoxic therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', 'DDInter', 'Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms such as fever, chills, shortness of breath, fatigue, and any unusual bleeding or bruising.', 'Synergism', 'Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/393/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (394, 'Zidovudine', 'Osimertinib', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/394/', '', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (395, 'Zidovudine', 'Oxaliplatin', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/395/', '', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Dolutegravir, More', 'Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (396, 'Zidovudine', 'Oxazepam', 'Minor', 'One study has suggested that patients receiving zidovudine and a benzodiazepine concomitantly may demonstrate increased plasma clearance of the benzodiazepine. That study also has suggested that patients on concomitant therapy may experience an increased number of headaches.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/396/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Meprobamate, Buspirone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (397, 'Zidovudine', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/397/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Telaprevir, Velpatasvir, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (398, 'Zidovudine', 'Paclitaxel', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/398/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Brincidofovir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (399, 'Zidovudine', 'Paclitaxel (protein-bound)', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/399/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (400, 'Zidovudine', 'Pazopanib', 'Moderate', 'Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity. Zidovudine has been associated with hematologic toxicities such as: neutropenia, granulocytopenia and severe anemia that required blood transfusions particularly in patients with advanced HIV disease.', 'DDInter', 'Hematological parameters should be closely monitored. Some authorities recommend dosages of one or both agents may be adjusted if necessary.', 'Synergism', 'Hematological parameters should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/400/', '', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, More', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, More', 1767369485);
